EAPLG
Regimen
Age < 60 and WBC < 10,000/uL
Induction therapy
All trans retinoic acid (ATRA) 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
Cytarabine (Ara-C) 200 mg/m2/d civi d3-9
Daunorubicin 60 mg/m2/d iv d3-5
Consolidation therapy
cycle 1
Cytarabine (Ara-C) 200 mg/m2/d civi d1-7
Daunorubicin 60 mg/m2/d iv d1-3
cycle 2
Cytarabine (Ara-C) 1000 mg/m2 iv q12h x 8 doses
Daunorubicin 45 mg/m2/d iv d1-3
Maintenance therapy
ATRA 45 mg/m2 po qd in 2 divided doses d1-15 q3m x 2 year
6-Mercaptopurine (6-MP) 90 mg/m2 po qd x 2 year
Methotrexate (MTX) 15 mg/m2 po qw x 2 year
Age < 60 and WBC > 10,000/uL
Induction therapy
ATRA 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
Cytarabine (Ara-C) 200 mg/m2/d civi d3-9
Daunorubicin 60 mg/m2/d iv d3-5
Consolidation therapy
cycle 1
Cytarabine (Ara-C) 200 mg/m2/d civi d1-7
Daunorubicin 60 mg/m2/d iv d1-3
Intrathecal cytarabine 50 mg and methotrexate 15 mg x 3
cycle 2
Cytarabine (Ara-C) 2000 mg/m2 iv q12h x 10 doses
Daunorubicin 45 mg/m2/d iv d1-3
Intrathecal cytarabine 50 mg and methotrexate 15 mg x 2
Maintenance therapy
ATRA 45 mg/m2 po qd in 2 divided doses d1-15 q3m x 2 year
6-Mercaptopurine (6-MP) 90 mg/m2 po qd x 2 year
Methotrexate (MTX) 15 mg/m2 po qw x 2 year
Age > 60 and WBC < 10,000/uL
Induction therapy
ATRA 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
Daunorubicin 60 mg/m2/d iv d3-5
Consolidation therapy
cycle 1
Daunorubicin 60 mg/m2/d iv d1-3
cycle 2
Daunorubicin 45 mg/m2/d iv d1-3
Maintenance therapy
ATRA 45 mg/m2 po qd in 2 divided doses d1-15 q3m x 2 year
6-Mercaptopurine (6-MP) 90 mg/m2 po qd x 2 year
Methotrexate (MTX) 15 mg/m2 po qw x 2 year
Age > 60 and WBC > 10,000/uL
Induction therapy
ATRA 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
Cytarabine (Ara-C) 200 mg/m2/d civi d3-9
Daunorubicin 60 mg/m2/d iv d3-5
Consolidation therapy
cycle 1
Cytarabine (Ara-C) 200 mg/m2/d civi d1-7
Daunorubicin 60 mg/m2/d iv d1-3
Intrathecal cytarabine 50 mg and methotrexate 15 mg x 3
cycle 2
Cytarabine (Ara-C) 1000 mg/m2 iv q12h x 8 doses
Daunorubicin 45 mg/m2/d iv d1-3
Intrathecal cytarabine 50 mg and methotrexate 15 mg x2
Maintenance therapy
ATRA 45 mg/m2 po qd in 2 divided doses d1-15 q3m x 2 year
6-Mercaptopurine (6-MP) 90 mg/m2 po qd x 2 year
Methotrexate (MTX) 15 mg/m2 po qw x 2 year
